Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-ThalassemiaKevin H.M. Kuo, Elliott Vichinsky, D. Mark Layton et al.|Blood|2021Cited by 7
P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIAKevin H.M. Kuo, Maria Domenica Cappellini, D. Mark Layton et al.|HemaSphere|2022Cited by 6
Exome Array Analysis of 9721 Ischemic Stroke Cases from the SiGN ConsortiumHuichun Xu, Braxton D. Mitchell, Yao Hu et al.|Genes|2022Cited by 4
Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in ProgressKevin H.M. Kuo, Elliott Vichinsky, D. Mark Layton et al.|Blood|2019Cited by 2
S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIAKevin H.M. Kuo, Elliott Vichinsky, D. Mark Layton et al.|HemaSphere|2022Cited by 1